Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print

Breaking News

Related Searches:
March 18, 2010
Centers to focus on three areas of expertise: Sterile & Specialty Products, Semi-solids & Liquids, and R&D  Read More »
March 18, 2010
Teva Pharmaceutical Industries has bid to acquire Germany-based generic drug manufacturer Ratiopharm, for an estimated $5.0 billion.   Read More »
March 18, 2010
John E. Murphy has been appointed head of clinical analytics within Quintiles’ consulting business.   Read More »
March 18, 2010
Marc Kamin, M.D., has been appointed vice president, Medical and Scientific Affairs, Neuroscience, PharmaNet Development Group.   Read More »
March 18, 2010
PPD and Southern Research Institute have entered into a collaborative agreement for pandemic and seasonal influenza vaccine R&D in an effort to provide clients with a full spectrum of vaccine development services.  Read More »
March 17, 2010
New unit adds 110 beds to capacity.  Read More »
March 17, 2010
First pact between the companies will evaluate SNALP's delivery of siRNA molecules.  Read More »
March 17, 2010
New indication for RA biologic  Read More »
March 17, 2010
Pharmacogenetics study sought poor drug metabolizers for study of neurological treatment.  Read More »
March 16, 2010
Jubilant Organosys’ two contract manufacturing facilities in North America have successfully completed regulatory cGMP audits.   Read More »
March 16, 2010
ICON will open an office in Manila, Philippines, further expanding its footprint in the Asia-Pacific region.  Read More »
March 16, 2010
Quintiles has relocated its Global Central Lab in Japan from Saitama to Tokyo to allow for further expansion.  Read More »
March 16, 2010
Savient Pharmaceuticals has resubmitted its BLA for Krystexxa after a CRL in July 2009  Read More »
March 15, 2010
Revenues from commercial operations increased 9% to $128.1 million in the quarter, aided by currency fluctuations.  Read More »
March 15, 2010
Amylin Pharmaceuticals, Lilly and Alkermes received a complete response letter from the FDA for their NDA for Bydureon (exenatide extended-release injectable suspension).  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On